Charles Schwab Investment Management Inc. Acquires 56,113 Shares of BioNTech SE Sponsored ADR $BNTX

Key Points

• Charles Schwab Investment Management Inc. increased its stake in BioNTech SE by 30% in the first quarter, owning 243,468 shares valued at approximately $22.17 million.
• Several institutional investors, including Bank of New York Mellon Corp, saw significant increases in their holdings of BioNTech, with one firm boosting its stake by 18,892.9%.
• BioNTech reported a revenue surge of 102.6% year-over-year, despite missing earnings estimates with a loss of ($1.60) EPS, while analysts maintain a Moderate Buy rating with an average target price of $135.80.

Charles Schwab Investment Management Inc. raised its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 30.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 243,468 shares of the company's stock after acquiring an additional 56,113 shares during the period. Charles Schwab Investment Management Inc. owned about 0.10% of BioNTech worth $22,170,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in BNTX. Banque Cantonale Vaudoise acquired a new position in BioNTech in the 1st quarter valued at approximately $36,000. Costello Asset Management INC bought a new stake in shares of BioNTech in the 1st quarter valued at approximately $91,000. Goodman Advisory Group LLC bought a new position in BioNTech in the 1st quarter valued at $105,000. Whittier Trust Co. raised its stake in BioNTech by 3,846.2% during the 1st quarter. Whittier Trust Co. now owns 2,052 shares of the company's stock worth $187,000 after buying an additional 2,000 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of BioNTech by 61.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock valued at $214,000 after acquiring an additional 713 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Trading Down 1.2%

BioNTech stock traded down $1.28 during trading hours on Tuesday, reaching $103.80. 596,453 shares of the company's stock were exchanged, compared to its average volume of 926,052. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The firm's 50 day simple moving average is $109.87 and its 200 day simple moving average is $105.29. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $131.49. The firm has a market capitalization of $24.95 billion, a PE ratio of -64.95 and a beta of 1.23.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The company had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. During the same quarter last year, the firm posted ($3.36) EPS. BioNTech's revenue for the quarter was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. Research analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Bank of America increased their price target on BioNTech from $126.00 to $134.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. Morgan Stanley increased their price target on BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Wells Fargo & Company set a $150.00 price target on BioNTech and gave the company an "overweight" rating in a research note on Tuesday, August 5th. Finally, Leerink Partners set a $112.00 price target on BioNTech in a research note on Monday, June 2nd. Thirteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $135.80.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.